There are 2867 resources available
564P - Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial
Presenter: Min Zheng
Session: Poster session 09
565P - Survival analysis of patients with locally advanced cervical cancer treated with cisplatin and gemcitabine concomitantly to radiotherapy followed by consolidation chemotherapy
Presenter: Flavia Alencar
Session: Poster session 09
566P - Stage IVB cervical cancer: Does definitive chemoradiation effect oncological outcomes?
Presenter: Shira Peleg Hasson
Session: Poster session 09
567P - Phase Ib study of Intraperitoneal (IP) administration of nivolumab plus ipilimumab in patients with recurrent gynaecologic malignancies with peritoneal involvement
Presenter: Emily Hinchcliff
Session: Poster session 09
568P - First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer
Presenter: Bo Zhu
Session: Poster session 09
569P - Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Real-life clinical experience
Presenter: Samantha Poblete
Session: Poster session 09
570P - Hypomethylating agents synergistically combine with PARP inhibitors in ovarian cancer
Presenter: Jenny Hong
Session: Poster session 09
571P - BRCA and beyond: Wider genetic testing of women with epithelial ovarian cancer
Presenter: Nicola Flaum
Session: Poster session 09
572P - High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer
Presenter: Wilko Weichert
Session: Poster session 09